Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to -$295000.0.

  • Ani Pharmaceuticals' Other Operating Expenses changed N/A to -$295000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $291.3 million, marking a year-over-year increase of 4425.2%. This contributed to the annual value of $312.2 million for FY2024, which is N/A changed from last year.
  • Ani Pharmaceuticals' Other Operating Expenses amounted to -$295000.0 in Q3 2025.
  • Ani Pharmaceuticals' 5-year Other Operating Expenses high stood at $108.6 million for Q4 2024, and its period low was -$8.4 million during Q2 2021.
  • For the 5-year period, Ani Pharmaceuticals' Other Operating Expenses averaged around $52.3 million, with its median value being $58.0 million (2023).
  • In the last 5 years, Ani Pharmaceuticals' Other Operating Expenses crashed by 12446.91% in 2021 and then skyrocketed by 67232.14% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Other Operating Expenses (Quarter) stood at -$350000.0 in 2021, then skyrocketed by 13835.71% to $48.1 million in 2022, then soared by 46.85% to $70.6 million in 2023, then skyrocketed by 53.81% to $108.6 million in 2024, then plummeted by 100.27% to -$295000.0 in 2025.
  • Its Other Operating Expenses stands at -$295000.0 for Q3 2025, versus $99.2 million for Q2 2025 and $83.8 million for Q1 2025.